These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 7517542

  • 1. Prostatic cancer and BPH.
    Brown SA.
    Postgrad Med; 1994 Jul; 96(1):24-5. PubMed ID: 7517542
    [No Abstract] [Full Text] [Related]

  • 2. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF, Mensink HJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1733-8. PubMed ID: 10494319
    [Abstract] [Full Text] [Related]

  • 3. [Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer].
    Hübler J, Jávor A.
    Orv Hetil; 1993 Jul 11; 134(28):1529-32. PubMed ID: 7688112
    [Abstract] [Full Text] [Related]

  • 4. [Prostate-specific antigen and prostatic cancer].
    Otnes B, Tveter KJ.
    Tidsskr Nor Laegeforen; 1994 Mar 10; 114(7):829. PubMed ID: 7516585
    [No Abstract] [Full Text] [Related]

  • 5. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L, Fang Z, Song J, Deng S.
    Zhonghua Wai Ke Za Zhi; 1999 Jan 10; 37(1):47-9. PubMed ID: 11829778
    [Abstract] [Full Text] [Related]

  • 6. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA, Kamalov AA, Karpov VK, Riaboĭ AV, Prokhorov AV.
    Urologiia; 2001 Jan 10; (2):37-40. PubMed ID: 11490716
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer detection in BPH patients.
    Puppo P, Perachino M, Ricciotti G, Bozzo W.
    Arch Esp Urol; 1994 Nov 10; 47(9):867-72. PubMed ID: 7530942
    [Abstract] [Full Text] [Related]

  • 8. Study supports PSA velocity risk count.
    Fillon M.
    J Natl Cancer Inst; 2012 Jul 18; 104(14):1042-3. PubMed ID: 22781432
    [No Abstract] [Full Text] [Related]

  • 9. Management of BPH: educating patients about PSA.
    Malvea BP.
    Am Fam Physician; 1996 Mar 18; 53(4):1080, 1082. PubMed ID: 8629559
    [No Abstract] [Full Text] [Related]

  • 10. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q, Yao DH, Jiang YQ.
    Zhonghua Nan Ke Xue; 2002 Dec 18; 8(6):411-3. PubMed ID: 12593013
    [Abstract] [Full Text] [Related]

  • 11. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y.
    Hinyokika Kiyo; 1999 Jul 18; 45(7):457-61. PubMed ID: 10466060
    [Abstract] [Full Text] [Related]

  • 12. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB, Oesterling JE.
    Urol Clin North Am; 1995 May 18; 22(2):333-44. PubMed ID: 7539179
    [Abstract] [Full Text] [Related]

  • 13. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM, Boeckmann W, Effert PJ, Habib FK, Jakse G.
    Anticancer Res; 1997 May 18; 17(4B):2993-4. PubMed ID: 9329583
    [Abstract] [Full Text] [Related]

  • 14. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL, Deng FM, Feng T.
    Zhonghua Yi Xue Za Zhi; 1994 May 18; 74(5):306-8, 327. PubMed ID: 7525028
    [Abstract] [Full Text] [Related]

  • 15. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu, Rasner PI, Skobelev PP.
    Urologiia; 2001 May 18; (6):48-54. PubMed ID: 11785083
    [No Abstract] [Full Text] [Related]

  • 16. [The evaluation of the ratio of free and total serum prostate-specific antigen as an additional method in the diagnosis of prostatic cancer].
    Reznikov IuP, Mazanov GP, Sedova TN.
    Urol Nefrol (Mosk); 1996 May 18; (6):41-3. PubMed ID: 9036610
    [Abstract] [Full Text] [Related]

  • 17. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA, Kuriyama M.
    Hinyokika Kiyo; 1998 Apr 18; 44(4):223-32. PubMed ID: 9617617
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G, Destefanis P, Procida S, Mandili G, Ulliers D, Ceruti C, Fiori C, Maule MM, Fontana D, Giribaldi G, Turrini F.
    BJU Int; 2008 Dec 18; 102(11):1566-72. PubMed ID: 18549428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.